Glaxo SmithKline (GSK Egypt) announced plans to inaugurate two production lines with investments worth EGP 100 million. The company will open a new line for producing Voltaren with investments amounting to EGP 20 million during 2019. In addition GSK Egypt will also inaugurate a new line at El-Salam factory for the production of Otrivin with EGP 80 million in investments during 2020. Earlier, the company's chairman Amr Mamdouh revealed a plan to launch three new production lines valued at EGP 180 million in 2019 and 2020. He noted that the company's total investments in Egypt reached $800 million.